Skip to main content

SpyGlass Pharma, Inc.

SGP
Exchange
Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0001778922

In the last 90 days, SpyGlass Pharma, Inc. insiders filed 1 open-market purchase and 0 sales; 69 institutions reported holding it in 13F filings for Q3 2026, worth $687.8M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 19, 2026
$1.03B
Insider buysLast 90 days, $32.4K in total
1
Insider sellsOpen market, last 90 days
0
13F holdersQ3 2026, +18 vs. previous quarter
69
13F valueReported value at the end of Q3 2026
$687.8M
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
–
No comparable prior period
Net income, FY2025
-$39.9M
No comparable prior period
Free cash flow, FY2025
-$33.5M
No comparable prior period
Revenue, Q3 FY2026
–
No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
1.16M
Shares sold short
Change
−63.8K
−5.2% vs. previous
Days to cover
12.05
At average daily volume

Superinvestors holding SGP, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding SGP at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by SpyGlass Pharma, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 18, 2026 (view filing)4:56 PM ETNov 162 daysRA Capital Healthcare Fund LP and 4 othersDirector, 10% OwnerPPurchase+1.00K$32.43+$32.4K0.0%5.97M after
Feb 11, 2026 (view filing)5:15 PM ETFeb 92 daysRA Capital Healthcare Fund LP and 4 othersDirector, 10% OwnerPPurchase+3.69M$16.00+$59.0MNew position2.05M after2 lots
Feb 11, 2026 (view filing)4:30 PM ETFeb 92 daysNew Enterprise Associates 17, L.P. and 2 others10% OwnerPPurchase+937.5K$16.00+$15.0M+18.4%6.04M afterDuplicate filing
Feb 11, 2026 (view filing)Feb 92 daysKhan Bilal ArshadDirectorPPurchase+20.0K$16.00+$320.0K+367.0%25.4K after
Feb 11, 2026 (view filing)Feb 92 daysKhan Bilal ArshadDirectorPPurchase+115.0K$16.00+$1.84M+84.3%251.4K after
Feb 11, 2026 (view filing)Feb 92 daysPardo Geoffrey BDirectorPPurchase+312.5K$16.00+$5.00M+16.7%2.19M after
Feb 11, 2026 (view filing)Feb 92 daysBehbahani AliDirector, 10% OwnerPPurchase+937.5K$16.00+$15.0M+18.4%6.04M afterDuplicate filing
Feb 11, 2026 (view filing)Feb 92 daysFlorence Anthony A. Jr.10% OwnerPPurchase+937.5K$16.00+$15.0M+18.4%6.04M afterDuplicate filing
Feb 11, 2026 (view filing)Feb 92 daysBaskett Forest10% OwnerPPurchase+937.5K$16.00+$15.0M+18.4%6.04M afterDuplicate filing
Feb 11, 2026 (view filing)Feb 92 daysYang Rick10% OwnerPPurchase+937.5K$16.00+$15.0M+18.4%6.04M afterDuplicate filing

Top 10 13F holders, Q3 2026

See all 69 holders

The largest institutional positions in SpyGlass Pharma, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding SGP in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Ra Capital Management, L.P.8,021,117$208.5M2.09%00.0%Unchanged
NEA Management Company, LLC7,392,301$192.2M14.09%00.0%Unchanged
Sands Capital Ventures, LLC2,500,012$65.0M9.36%00.0%Unchanged
Samsara BioCapital, LLC2,109,953$54.9M5.22%00.0%Unchanged
JPMorgan Chase & Co1,003,268$25.5M0.00%+373,529+59.3%Added
Price T Rowe Associates Inc925,767$24.1M0.00%+251,624+37.3%Added
Vanguard Capital Management LLC660,821$17.2M0.00%+226,398+52.1%Added
Vestal Point Capital, LP640,000$16.6M0.43%−30,000−4.5%Reduced
BlackRock, Inc.630,409$16.4M0.00%−81,303−11.4%Reduced
Standard Life Aberdeen plc506,502$13.2M0.02%+13,426+2.7%Added

Holders of 5% or more of SGP

See all 6 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of SpyGlass Pharma, Inc..

Largest holders of SGP from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Ra Capital Management, L.P.13D24.10%8.02M sharesNewFeb 17, 20261 filingFeb 17, 2026SEC
New Enterprise Associates 17, L.P.13D22.20%7.39M sharesNewFeb 13, 20261 filingFeb 13, 2026SEC
Vensana Capital I GP, LLC13D/A8.90%2.99M shares−1.00 ppfrom 9.90%Feb 10, 20262 filingsNov 18, 2026SEC
Sands Capital Life Sciences Pulse Fund III (DE), L.P.13G7.80%2.50M sharesNewFeb 13, 20261 filingFeb 13, 2026SEC
Gilde Healthcare Holding B.V.13D6.57%2.19M sharesNewFeb 13, 20261 filingFeb 13, 2026SEC